Trial Profile
Portal hemodynamic effects of regorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Liver cancer
- Focus Pharmacodynamics
- 26 Apr 2020 Status changed from recruiting to completed.
- 22 Apr 2018 Status changed from not yet recruiting to recruiting.
- 03 Nov 2017 New trial record